复发多发性骨髓瘤对免疫调节药物和蛋白酶体抑制剂难治的自然病史:一项多中心IMWG研究
这项多中心IMWG研究纳入2006至2014年诊断的543例复发多发性骨髓瘤患者,均接受过至少3线治疗、对一种免疫调节药物(来那度胺或泊马度胺)和一种蛋白酶体抑制剂(硼替佐米或卡非佐米)难治,并曾暴露于烷化剂。从符合上述标准的时间点(T0)起,整个队列的中位总生存期为13个月(95%CI 11,15)。462例(85%)患者在T0后至少记录到一种方案,其中位无进展生存期和总生存期分别为5个月(95%CI 4,6)和15.2个月(95%CI 13,17)。
要点
- T0时中位年龄62岁(范围31-87),61%为男性,诊断至T0中位时间3.1年。
- T0前中位治疗线数为4(范围3-13)。
- 整个队列从T0起中位总生存期为13个月(95%CI 11,15)。
核心结论
- 该研究提供了对蛋白酶体抑制剂和免疫调节药物均难治的复发多发性骨髓瘤的预期结局,可作为比较正在评估的新疗法的基准。
研究设计与样本
- 多中心IMWG研究,纳入2006至2014年诊断的543例复发多发性骨髓瘤患者,均接受过至少3线治疗、对一种免疫调节药物(来那度胺或泊马度胺)和一种蛋白酶体抑制剂(硼替佐米或卡非佐米)难治,并曾暴露于烷化剂;符合上述标准的时间定义为T0。
主要发现
- T0时中位年龄62岁(范围31-87),61%为男性。
- 诊断至T0的中位时间为3.1年。
- T0前中位治疗线数为4(范围3-13)。
- 整个队列从T0起中位总生存期为13个月(95%CI 11,15)。
- 462例(85%)患者在T0后至少记录到一种方案,其中位无进展生存期为5个月(95%CI 4,6),中位总生存期为15.2个月(95%CI 13,17)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.
引用
- Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017. PMID: 28620163. doi:10.1038/leu.2017.138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。